Search: onr:"swepub:oai:DiVA.org:umu-32456" >
Atorvastatin and pe...
Atorvastatin and persistent atrial fibrillation following cardioversion : a randomized placebo-controlled multicentre study
-
- Almroth, Henrik (author)
- Örebro universitet,Hälsoakademin
-
- Höglund, Niklas (author)
- Department of Cardiology, Heart Centre, University Hospital, S-901 85 Umeå, Sweden
-
- Boman, Kurt (author)
- Umeå universitet,Medicin
-
show more...
-
Englund, Anders (author)
-
- Jensen, Steen (author)
- Department of Cardiology, Heart Centre, University Hospital, S-901 85 Umeå, Sweden
-
- Kjellman, Björn (author)
- Karolinska Institutet
-
- Tornvall, Per (author)
- Karolinska Institutet
-
- Rosenqvist, Mårten (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2008-12-09
- 2009
- English.
-
In: European Heart Journal. - Philadelphia : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 30:7, s. 827-833
- Related links:
-
https://academic.oup...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- AIMS: To evaluate the effect of atorvastatin in achieving stable sinus rhythm (SR) 30 days after electrical cardioversion (CV) in patients with persistent atrial fibrillation (AF). METHODS AND RESULTS: The study included 234 patients. The patients were randomized to treatment with atorvastatin 80 mg daily (n = 118) or placebo (n = 116) in a prospective, double-blinded fashion. Treatment was initiated 14 days before CV and was continued 30 days after CV. The two groups were well-balanced with respect to baseline characteristics. Mean age was 65 +/- 10 years, 76% of the patients were male and 4% had ischaemic heart disease. Study medication was well-tolerated in all patients but one. Before primary endpoint 12 patients were excluded. In the atorvastatin group 99 patients (89%) converted to SR at electrical CV compared with 95 (86%) in the placebo group (P = 0.42). An intention-to-treat analysis with the available data, by randomization group, showed that 57 (51%) in the atorvastatin group and 47 (42%) in the placebo group were in SR 30 days after CV (OR 1.44, 95%CI 0.85-2.44, P = 0.18). CONCLUSION: Atorvastatin was not statistically superior to placebo with regards to maintaining SR 30 days after CV in patients with persistent AF.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Atrial fibrillation
- Randomized
- Cardioversion
- Trials
- Placebo-controlled
- Lipids
- MEDICINE
- MEDICIN
- Cardiology
- Cardiology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database